Sugi Predict

Sugi Predict / Compounds / SCHEMBL5442050

SCHEMBL5442050

SCHEMBL5442050

CC(=O)c1cc(NC(=O)CCCCCCCCC(N)=O)cc(C(C)=O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FURIN P09958 6/20 0.56
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ F10 P00742 1/20 0.52
▸ PARP1 P09874 1/20 0.50
▸ PARP10 Q53GL7 1/20 0.50
▸ HDAC3 O15379 1/20 0.47
▸ HDAC4 P56524 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC7 Q8WUI4 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47
▸ HDAC10 Q969S8 1/20 0.47
▸ HDAC11 Q96DB2 1/20 0.47
▸ HDAC8 Q9BY41 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ HDAC9 Q9UKV0 1/20 0.47
▸ HDAC5 Q9UQL6 1/20 0.47
▸ LMNA P02545 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8446705 1.00 FURIN (0.56) FURINMEN1KMT2AF10PARP1
SCHEMBL8445590 1.00 FURIN (0.56) FURINMEN1KMT2AF10PARP1
SCHEMBL6149232 1.00 FURIN (0.56) FURINMEN1KMT2AF10PARP1
SCHEMBL5973917 1.00 FURIN (0.56) FURINMEN1KMT2AF10PARP1
SCHEMBL5973945 0.98 FURIN (0.56) FURINMEN1KMT2AF10PARP1
SCHEMBL6150719 0.95 FURIN (0.56) FURINMEN1KMT2AF10PARP1
SCHEMBL5973841 0.93 FURIN (0.55) FURINMEN1KMT2AF10PARP1
SCHEMBL5974478 0.93 FURIN (0.55) FURINMEN1KMT2AF10PARP1
SCHEMBL4914693 0.93 FURIN (0.55) FURINMEN1KMT2AF10PARP1
SCHEMBL5974904 0.93 FURIN (0.55) FURINMEN1KMT2AF10PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1255541-B1 AROMATIC GUANYLHYDRAZONE FOR THE TREATMENT OF RESISTANT VIRAL INFECTIONS BEVEC DORIAN (DE) 2005-11-09 — — EP claimed
WO-2004016258-A1 THERAPEUTICAL USE OF GUANYLHYDRAZONES FOR TREATING DISEASES ASSOCIATED WITH DENDRITIC CELL MATURATION MONDOBIOTECH LABORATORIES ANSTALT (CH) 2004-02-26 — — WO claimed
US-20030203969-A1 Pharmaceutically active aromatic guanylhydrazones AXXIMA PHARMACEUTICALS AG (DE) 2003-10-30 — — US claimed
WO-2003006426-A1 AROMATIC GUANYLHYDRAZONES AS EFFECTIVE COMPOUNDS AGAINST NEURODISEASES AXXIMA PHARMACEUTICALS AG (DE) 2003-01-23 — — WO claimed
EP-1255541-A2 PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES Axxima Pharmaceuticals Aktiengesellschaft (DE) 2002-11-13 — — EP claimed
WO-2002000613-A2 INHIBITORS OF HEPATITIS B VIRUS INFECTION AXXIMA PHARMACEUTICALS AG (DE) 2002-01-03 — — WO claimed
WO-2001056553-A2 PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES AXXIMA PHARMACEUTICALS AG (DE) 2001-08-09 — — WO claimed
US-20070213350-A1 Method of treating ileus by pharmacological activation of cholinergic receptors TRACEY KEVIN J 2007-09-13 — — US disclosed
EP-1773304-A2 METHOD OF TREATING ILEUS BY PHARMACOLOGICAL ACTIVATION OF CHOLINERGIC RECEPTORS The Feinstein Institute for Medical Research (US) 2007-04-18 — — EP disclosed
EP-1734941-A2 NEURAL TOURNIQUET The Feinstein Institute for Medical Research (US) 2006-12-27 — — EP disclosed
WO-2006002375-A2 METHOD OF TREATING ILEUS BY PHARMACOLOGICAL ACTIVATION OF CHOLINERGIC RECEPTORS THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) 2006-01-05 — — WO disclosed
US-20050282906-A1 Neural tourniquet NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE (US) 2005-12-22 — — US disclosed
EP-1255541-B1 AROMATIC GUANYLHYDRAZONE FOR THE TREATMENT OF RESISTANT VIRAL INFECTIONS BEVEC DORIAN (DE) 2005-11-09 — — EP disclosed
EP-1255541-A2 PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES Axxima Pharmaceuticals Aktiengesellschaft (DE) 2002-11-13 — — EP disclosed
WO-2002000613-A2 INHIBITORS OF HEPATITIS B VIRUS INFECTION AXXIMA PHARMACEUTICALS AG (DE) 2002-01-03 — — WO disclosed
WO-2001056553-A2 PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES AXXIMA PHARMACEUTICALS AG (DE) 2001-08-09 — — WO disclosed
EP-0746312-A4 GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS PICOWER INST MED RES (US) 1999-05-26 — — EP disclosed
US-5854289-A Guanylhydrazones and their use to treat inflammatory conditions THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) 1998-12-29 — — US disclosed
EP-0746312-A1 GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) 1996-12-11 — — EP disclosed
WO-1995019767-A1 GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) 1995-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203969-A1 Pharmaceutically active aromatic guanylhydrazones DHPS, GGPS1, GMPS FURIN 2883/4885MEN1 4245/4885KMT2A 4547/4885
US-20070213350-A1 Method of treating ileus by pharmacological activation of cholinergic receptors ACHE, CHRM3, CHRM5 FURIN 4054/4885MEN1 2284/4885KMT2A 1247/4885
US-20050282906-A1 Neural tourniquet ACHE, CHAT, TFPI FURIN 792/4885MEN1 2732/4885KMT2A 718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.